The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).
Luis G Paz-Ares, Edward B Garon, Andrea Ardizzoni, Fabrice Barlesi, Byoung Chul Cho, Gilberto Castro, Pedro De Marchi, Enriqueta Felip, Yasushi Goto, Alastair Greystoke, Shun Lu, Darren Wan Teck Lim, Vassiliki Papadimitrakopoulou, Martin Reck, Benjamin J Solomon, David R Spigel, Daniel Shao-Weng Tan, Michael Thomas, James Chih-Hsin Yang, Bruce E Johnson
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019
TPS9124 Background: Inflammatory pathways can be pro-tumorigenic or anti-tumorigenic. The cytokine interleukin-1β (IL-1β) can promote the infiltration of immunosuppressive cells into the tumor microenvironment leading to a pro-tumorigenic microenvironment that promotes carcinogenesis, tumor invasiveness, and immunosuppression. Canakinumab is a human monoclonal antibody that binds and neutralizes IL-1β. Previous clinical data (CANTOS study) has shown that canakinumab could significantly reduce lung cancer incidence and mortality. This data along with the preclinical results that IL-1β does support tumorigenic inflammation provide the rationale to investigate the therapeutic role of canakinum..View full abstract